A Phase 2/3 interventional study of Bexagliflozin and Placebo in Essential Hypertension, sponsored by Theracos. Completed at 87 sites in United States. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2021-09-21.
Sponsored by Theracos · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Essential Hypertension with a site in United States — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Hypertension · United States.
Among the 53 studies in Essential Hypertension with a site in United States, this one is the 11th largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2017, is the only one in phase 2/3, and was the 36th registered.
481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.
Browse Essential Hypertension studies →8 of the 53 studies in Essential Hypertension with a site in United States are open now. Recruiting first, the newest first:
Faith A. Richardson · Sites in United States
Ages 21–80 · Healthy volunteers
National Human Genome Research Institute (NHGRI) · Sites in United States
Ages 2–99
ReCor Medical, Inc. · Sites in United States
Ages 18+
Orchestra BioMed, Inc · Sites in United States, Australia, Belgium and 12 more countries
Ages 18+
University of Pittsburgh · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 8 · Phase 3 15 · Phase 4 1
First in 1995; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 673 is above the median of 144 across 408 interventional studies indexed under Essential Hypertension.
Median enrollment 275 across the 46 interventional studies, 1,000 across the 7 observational. Of the 41 that completed or were terminated, 23 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 53 have an industry lead sponsor. The 10 most frequent:
Theracos is the lead sponsor of 21 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 9 (100%) have results posted.
Theracos has 1 study filed under Essential Hypertension — fewer than ten, so there is no comparison to draw.
3 of the studies in Essential Hypertension with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06059638Orchestra BioMed, IncBradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | 2026-12 |
| NCT05546931University of PittsburghMobile Health Program for Rural Hypertension | 2026-12 |
| NCT04505618Johns Hopkins UniversityOptical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 53 studies in Essential Hypertension with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This integrated assessment consists of two studies, 603A and 603B, to be carried out sequentially in a common study population. Participating subjects informed of the trial design and their consent to participate in both studies were to be obtained in a single consent form. Approximately 680 male or female adult subjects were to be enrolled.
THR-1442-C-603 is an integrated assessment of the potential utility of bexagliflozin tablets, 20 mg for the treatment of essential hypertension. It is composed of two studies, 603A and 603B, measuring effects in a common population.
603A was a multicenter double-blind parallel group placebo-controlled study conducted to determine the placebo-adjusted change from baseline to week 12 in the mean ambulatory systolic blood pressure (SBP) of approximately 680 subjects considered generally representative of the adult hypertensive population in the United States. Secondary endpoints included the placebo-adjusted change from baseline to week 12 of the mean office seated systolic blood pressure, the change to week 12 of the mean ambulatory and mean office seated diastolic blood pressure, the proportion of subjects achieving prespecified goals for absolute systolic and diastolic blood pressure as well as prespecified goals for reduction in systolic and diastolic blood pressure, measured by ambulatory and seated office measurement methodology.
A603B was a multicenter double-blind parallel group placebo-controlled randomized withdrawal study conducted to determine the durability of the antihypertensive effect of bexagliflozin tablets, 20 mg, in a population not pre-selected for existing diabetes. All subjects entered a 12 week run-in period during which they self-administered open label bexagliflozin tablets, 20 mg once daily. At week 12 a baseline ambulatory blood pressure monitoring (ABPM) measurement was made, and the subjects were randomized one to one to receive either bexagliflozin tablets, 20 mg or bexagliflozin tablets, placebo. After a 12 week treatment period a second ABPM measurement was made. The primary endpoint was the intergroup difference in the change from baseline in the mean SBP.
To be eligible for randomization a prospective subject was to be:
Prospective participants exhibiting any of the following characteristics were to be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Period 1: Placebo Period 2: Bexagliflozin Period 3: Bexagliflozin
Drug: Bexagliflozin · Drug: Placebo
Period 1: Placebo Period 2: Bexagliflozin Period 3: Placebo
Drug: Bexagliflozin · Drug: Placebo
Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Bexagliflozin
Drug: Bexagliflozin
Period 1: Bexagliflozin Period 2: Bexagliflozin Period 3: Placebo
Drug: Bexagliflozin · Drug: Placebo
Bexagliflozin tablet, 20 mg
Also known as: EGT0001442
Placebo (inactive) tablet to match the active drug
Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12
Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo
Time frame: Baseline (Day 1) to week 12
Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36
Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo
Time frame: Change from week 24 to week 36
603A, Reduction of Mean Ambulatory Systolic Blood Pressure
Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater
Time frame: Baseline (Day 1) to week 12
603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less
Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less
Time frame: Baseline (Day 1) to week 12
603A, Change in Seated Office Systolic Blood Pressure
Placebo-adjusted change in seated office systolic blood pressure
Time frame: Baseline (Day 1) to week 12
603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less
Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less
Time frame: Baseline (Day 1) to week 12
603A, Change in Mean Ambulatory Diastolic Blood Pressure
Placebo-adjusted change in mean ambulatory diastolic blood pressure
Time frame: Baseline (Day 1) to week 12
603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less
Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less
Time frame: Baseline (Day 1) to week 12
603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater
Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater
Time frame: Baseline (Day 1) to week 12
603A, Change in Seated Office Diastolic Blood Pressure
Placebo-adjusted change in seated office diastolic blood pressure
Time frame: Baseline (Day 1) to week 12
603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less
Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less
Time frame: Baseline (Day 1) to week 12
603B, Change in Seated Office Systolic Blood Pressure
Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure
Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
603B, Change in Mean Ambulatory Diastolic Blood Pressure
Placebo-adjusted change in mean ambulatory diastolic blood pressure
Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
603B, Change in Seated Office Diastolic Blood Pressure
Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure
Time frame: Week 12 (cumulative week 24) to Week 24 (cumulative week 36)
Integrated 603A and 603B, Effects on Mean Ambulatory Systolic and Diastolic Blood Pressure
Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.
Time frame: Baseline (Day 1) to cumulative week 36
Integrated 603A and 603B, Effects on Seated Office Systolic and Diastolic Blood Pressure
Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time
Time frame: Baseline (Day 1) to cumulative week 36
| Milestone | 603A: Bexagliflozin Tablets, 20 mg | 603A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets |
|---|---|---|---|---|
| Started | 334 | 339 | 0 | 0 |
| Completed | 307 | 319 | 0 | 0 |
| Not completed | 27 | 20 | 0 | 0 |
| Withdrew: Protocol violation | 3 | 3 | 0 | 0 |
| Withdrew: Adverse event | 5 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 0 | 0 |
| Withdrew: Lost to follow-up | 10 | 9 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 |
| Withdrew: 24 hr abpm not enough readings | 0 | 1 | 0 | 0 |
| Milestone | 603A: Bexagliflozin Tablets, 20 mg | 603A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets |
|---|---|---|---|---|
| Started | 0 | 0 | 281 | 281 |
| Completed | 0 | 0 | 267 | 266 |
| Not completed | 0 | 0 | 14 | 15 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 3 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 2 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 6 | 6 |
| Withdrew: 24 hr abpm not enough readings | 0 | 0 | 3 | 3 |
Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared to placebo
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change of the 24 Hour Mean Systolic Blood Pressure From Baseline (Day 1) to Week 12 | -8.86 ± 0.642 | -6.15 ± 0.622 |
Change of the 24 hour mean systolic blood pressure in the bexagliflozin group compared placebo
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| Change of the 24 Hour Mean Systolic Blood Pressure From Cumulative Week 24 to Week 36 | 0.30 ± 0.680 | 2.74 ± 0.678 |
Proportion of subjects who achieve a reduction of mean ambulatory systolic blood pressure of 10 mm Hg or greater
| proportion of participants | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Reduction of Mean Ambulatory Systolic Blood Pressure | 0.40 (0.35 to 0.46) | 0.34 (0.29 to 0.40) |
Proportion of subjects who achieve a mean ambulatory systolic blood pressure of 135 mm Hg or less
| Proportion of subjects | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Mean Ambulatory Systolic Blood Pressure of 135 mm Hg or Less | 0.40 (0.34 to 0.46) | 0.29 (0.24 to 0.35) |
Placebo-adjusted change in seated office systolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Change in Seated Office Systolic Blood Pressure | -11.24 ± 0.799 | -6.61 ± 0.787 |
Proportion of subjects who achieve a seated office systolic blood pressure of 140 mm Hg or less
| Proportion of subjects | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Seated Office Systolic Blood Pressure of 140 mm Hg or Less | 0.38 (0.33 to 0.44) | 0.25 (0.21 to 0.30) |
Placebo-adjusted change in mean ambulatory diastolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Change in Mean Ambulatory Diastolic Blood Pressure | -3.92 ± 0.349 | -3.08 ± 0.337 |
Proportion of subjects who achieve a mean ambulatory diastolic blood pressure of 87 mm Hg or less
| Proportion of subjects | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Mean Ambulatory Diastolic Blood Pressure of 87 mm Hg or Less | 0.47 (0.41 to 0.53) | 0.37 (0.32 to 0.43) |
Proportion of subjects who achieve a reduction of mean ambulatory diastolic blood pressure of 4 mm Hg or greater
| Proportion of subjects | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Reduction of Mean Ambulatory Diastolic Blood Pressure of 4 mm Hg or Greater | 0.88 (0.83 to 0.92) | 0.80 (0.73 to 0.85) |
Placebo-adjusted change in seated office diastolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Change in Seated Office Diastolic Blood Pressure | -4.44 ± 0.504 | -2.13 ± 0.496 |
Proportion of subjects who achieve a mean seated office diastolic blood pressure of 90 mm Hg or less
| Proportion of subjects | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603A, Seated Office Diastolic Blood Pressure of 90 mm Hg or Less | 0.65 (0.59 to 0.71) | 0.53 (0.47 to 0.59) |
Placebo-adjusted change from week 12 to week 24 in seated office systolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603B, Change in Seated Office Systolic Blood Pressure | 1.98 ± 0.846 | 5.18 ± 0.859 |
Placebo-adjusted change in mean ambulatory diastolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603B, Change in Mean Ambulatory Diastolic Blood Pressure | 0.10 ± 0.369 | 0.94 ± 0.368 |
Placebo-adjusted change from week 12 to week 24 in seated office diastolic blood pressure
| mm Hg | Bexagliflozin Tablets, 20 mg | Placebo Tablets |
|---|---|---|
| 603B, Change in Seated Office Diastolic Blood Pressure | 0.51 ± 0.507 | 1.76 ± 0.514 |
Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on mean ambulatory systolic and diastolic blood pressure after 12 weeks of bexagliflozin treatment, as well as longer treatment periods, i.e., 24 weeks or 36 weeks of bexagliflozin treatment.
| mm Hg | Effect on Mean Ambulatory SBP | Effect on Mean Ambulatory DBP |
|---|---|---|
| 12 Weeks | -7.595 (-8.565 to -6.625) | -3.269 (-3.773 to -2.764) |
| 24 Weeks | -9.262 (-10.559 to -7.965) | -4.044 (-4.720 to -3.368) |
| 36 Weeks | -12.454 (-14.988 to -9.921) | -5.566 (-6.825 to -4.308) |
Integration of measures collected in studies 603A and 603B will be used to assess consistent effects on seated office systolic and diastolic blood pressure over time
| mm Hg | Effect on Seated Office SBP | Effect on Seated Office DBP |
|---|---|---|
| 6 Weeks | -8.43 ± 16.399 | -4.50 ± 9.534 |
| 12 Weeks | -9.91 ± 15.777 | -4.10 ± 9.716 |
| 18 Weeks | -14.46 ± 16.000 | -5.87 ± 9.282 |
| 24 Weeks | -12.53 ± 18.830 | -4.92 ± 10.910 |
| 36 Weeks | -15.71 ± 16.975 | -6.47 ± 9.933 |
Collected over For 603A, adverse events were collected from baseline to Week 12. For 603B, adverse events were collected from Week 24 to Week 36.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 603A: Bexagliflozin Tablets, 20 mg | 0/334 (0%) | 11/334 (3.3%) | 94/334 (28.1%) |
| 603A: Placebo Tablets | 0/339 (0%) | 10/339 (2.9%) | 88/339 (26%) |
| 603B: Bexagliflozin Tablets, 20 mg | 0/281 (0%) | 9/281 (3.2%) | 32/281 (11.4%) |
| 603B: Placebo Tablets | 0/281 (0%) | 6/281 (2.1%) | 37/281 (13.2%) |
| Event | 603A: Bexagliflozin Tablets, 20 mg | 603A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 0/334 | 0/339 | 2/281 | 0/281 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/334 | 0/339 | 0/281 | 1/281 |
| Myocardial infarctionCardiac disorders | 0/334 | 1/339 | 0/281 | 1/281 |
| Necrotising fasciitisInfections and infestations | 0/334 | 0/339 | 1/281 | 0/281 |
| Crohn's diseaseGastrointestinal disorders | 0/334 | 0/339 | 1/281 | 0/281 |
| Intestinal obstructionGastrointestinal disorders | 0/334 | 0/339 | 0/281 | 1/281 |
| Large intestine polypGastrointestinal disorders | 0/334 | 0/339 | 1/281 | 0/281 |
| Muscle ruptureMusculoskeletal and connective tissue disorders | 0/334 | 0/339 | 0/281 | 1/281 |
| Pelvic fractureInjury, poisoning and procedural complications | 0/334 | 0/339 | 1/281 | 0/281 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/334 | 1/339 | 0/281 | 1/281 |
| Event | 603A: Bexagliflozin Tablets, 20 mg | 603A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets |
|---|---|---|---|---|
| PollakiuriaRenal and urinary disorders | 13/334 | 4/339 | 0/281 | 0/281 |
| NasopharyngitisInfections and infestations | 12/334 | 11/339 | 4/281 | 2/281 |
| Upper respiratory tract infectionInfections and infestations | 5/334 | 10/339 | 1/281 | 3/281 |
| PolyuriaRenal and urinary disorders | 4/334 | 9/339 | 2/281 | 1/281 |
| Urinary tract infectionInfections and infestations | 7/334 | 7/339 | 6/281 | 6/281 |
| NauseaGastrointestinal disorders | 7/334 | 5/339 | 1/281 | 3/281 |
| DizzinessNervous system disorders | 7/334 | 1/339 | 3/281 | 1/281 |
| Oedema peripheralGeneral disorders | 3/334 | 7/339 | 0/281 | 1/281 |
| HeadacheNervous system disorders | 4/334 | 7/339 | 1/281 | 2/281 |
| ConstipationGastrointestinal disorders | 6/334 | 3/339 | 1/281 | 1/281 |
* To avoid being double-counting of the participants, the number of baseline participants has been entered as "0" for 603B. * Subjects in 603B study had completed 603A study and were qualified to be re-randomized in 603B study.
| Age, Continuous(years) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period | 59.4 ± 11.32 | 58.3 ± 12.06 | — | — | 58.9 ± 11.71 |
| 603B: 12-36 Week Study Period | — | — | 59.9 ± 11.39 | 59.2 ± 11.78 | 59.6 ± 11.58 |
| Sex: Female, Male(Participants) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period — Female | 127 | 139 | 0 | 0 | 266 |
| 603A: 0-12 Week Study Period — Male | 207 | 200 | 0 | 0 | 407 |
| 603B: 12-36 Week Study Period — Female | 0 | 0 | 110 | 114 | 224 |
| 603B: 12-36 Week Study Period — Male | 0 | 0 | 171 | 167 | 338 |
| Ethnicity (NIH/OMB)(Participants) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period — Hispanic or Latino | 27 | 27 | 0 | 0 | 54 |
| 603A: 0-12 Week Study Period — Not Hispanic or Latino | 307 | 312 | 0 | 0 | 619 |
| 603A: 0-12 Week Study Period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| 603B: 12-36 Week Study Period — Hispanic or Latino | 0 | 0 | 27 | 19 | 46 |
| 603B: 12-36 Week Study Period — Not Hispanic or Latino | 0 | 0 | 254 | 262 | 516 |
| 603B: 12-36 Week Study Period — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period — American Indian or Alaska Native | 0 | 2 | 0 | 0 | 2 |
| 603A: 0-12 Week Study Period — Asian | 7 | 4 | 0 | 0 | 11 |
| 603A: 0-12 Week Study Period — Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| 603A: 0-12 Week Study Period — Black or African American | 94 | 104 | 0 | 0 | 198 |
| 603A: 0-12 Week Study Period — White | 219 | 220 | 0 | 0 | 439 |
| 603A: 0-12 Week Study Period — More than one race | 4 | 3 | 0 | 0 | 7 |
| 603A: 0-12 Week Study Period — Unknown or Not Reported | 9 | 6 | 0 | 0 | 15 |
| 603B: 12-36 Week Study Period — American Indian or Alaska Native | 0 | 0 | 1 | 1 | 2 |
| 603B: 12-36 Week Study Period — Asian | 0 | 0 | 4 | 4 | 8 |
| 603B: 12-36 Week Study Period — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| 603B: 12-36 Week Study Period — Black or African American | 0 | 0 | 92 | 70 | 162 |
| 603B: 12-36 Week Study Period — White | 0 | 0 | 178 | 195 | 373 |
| 603B: 12-36 Week Study Period — More than one race | 0 | 0 | 2 | 4 | 6 |
| 603B: 12-36 Week Study Period — Unknown or Not Reported | 0 | 0 | 4 | 7 | 11 |
| Body Mass Index(kg/m^2) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period | 32.29 ± 6.522 | 32.90 ± 6.527 | — | — | 32.59 ± 6.527 |
| 603B: 12-36 Week Study Period | — | — | 32.22 ± 6.952 | 33.17 ± 6.144 | 32.69 ± 6.572 |
| Body Weight at Baseline(kg) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period | 95.36 ± 22.643 | 97.47 ± 22.673 | — | — | 96.42 ± 22.666 |
| 603B: 12-36 Week Study Period | — | — | 95.71 ± 24.321 | 97.55 ± 21.003 | 96.63 ± 22.721 |
| History of Diabetes(Participants) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period — Yes | 83 | 84 | — | — | 167 |
| 603A: 0-12 Week Study Period — No | 251 | 255 | — | — | 506 |
| 603B: 12-36 Week Study Period — Yes | — | — | 78 | 66 | 144 |
| 603B: 12-36 Week Study Period — No | — | — | 203 | 215 | 418 |
| Use of any antihypertension medication(Participants) | 603A: Bexagliflozin Tablets, 20 mg | 603 A: Placebo Tablets | 603B: Bexagliflozin Tablets, 20 mg | 603B: Placebo Tablets | Total |
|---|---|---|---|---|---|
| 603A: 0-12 Week Study Period | 269 | 276 | — | — | 545 |
| 603B: 12-36 Week Study Period | — | — | 233 | 226 | 459 |
3 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Nov 2018, 13 months.
Results were first posted in Sep 2021, 2 years 9 months after primary completion. A results delay was requested in Jan 2019.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bexagliflozin
Theracos